Undifferentiated iPSC Detection

A key concern in iPSC-based therapeutic applications is the safety of the cell products to be transplanted into patients. Although the in vivo teratoma formation assay is an effective method to directly assess the tumorigenicity of undifferentiated cells, it is also costly and time-consuming. Now, Creative Bioarray presents a quick and cost-effective assay to detect residual undifferentiated iPSCs amongst direct differentiated cells and cells intended to be used in transplantation activities.

We detect the undifferentiated iPS cells by measuring miRNA markers in the cell culture supernatants, which is non-destructive, but more sensitive than other testing methods. This technology could also be used for early cell selection, contributing to the improvement of production efficiency.